Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Two-stage, Two-arm, Open-Label Phase II Study of Venetoclax in Combination With Azacytidine in Acute Myeloid Leukemia Patients Selected Using Ex Vivo Drug Sensitivity Screening

Trial Profile

Two-stage, Two-arm, Open-Label Phase II Study of Venetoclax in Combination With Azacytidine in Acute Myeloid Leukemia Patients Selected Using Ex Vivo Drug Sensitivity Screening

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary) ; Azacitidine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms VenEx

Most Recent Events

  • 16 May 2025 Results assessing the feasibility of using fingertip capillary blood plasma, collected via microsampling, to measure venetoclax trough concentrations presented in the Basic and Clinical Pharmacology and Toxicology
  • 04 Sep 2024 Status changed from active, no longer recruiting to completed.
  • 15 Jun 2023 Results (n=36) assessing Capillary Blood Sampling for Venetoclax Concentration Measurement presented at the 28th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top